Lantheus Holdings, Inc. (LNTH) is scheduled to release fourth-quarter 2023 results on Feb 22, before the opening bell.
In the last reported quarter, Lantheus Holdings’ earnings per share of $1.47 surpassed the Zacks Consensus Estimate by 11.4%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, the average being 20.9%.
Factors at Play
On the third-quarter 2023 earnings call in November, Lantheus’ management confirmed that it has been continuing to register a robust uptick in sales of both PYLARIFY and DEFINITY. This is likely to have considerably driven the fourth-quarter revenues.
The continued favorable adoption of PSMA positron emission tomography (PET) with PYLARIFY is expected to have continued in the fourth quarter of 2023. This is likely to have considerably driven the fourth-quarter revenues.
It is worth mentioning that PYLARIFY is an F 18-labelled PSMA-targeted PET imaging agent used with PET or computed tomography, whereas DEFINITY is an injectable ultrasound-enhancing agent used in echocardiography examinations. Management also expects its F-18 labeled PET diagnostic imaging agent targeting tau-tangles for Alzheimer’s disease, MK-6240, to have maintained its momentum in the to-be-reported quarter.
It is worth mentioning that PYLARIFY is an F 18-labelled PSMA-targeted PET imaging agent used with PET or computed tomography, whereas DEFINITY is an injectable ultrasound-enhancing agent used in echocardiography examinations. Management also expects its F-18 labeled PET diagnostic imaging agent targeting tau-tangles for Alzheimer’s disease, MK-6240, (which was granted Fast Track designation by the FDA) to have maintained its momentum in the to-be-reported quarter.
Lantheus is working closely with its partner, POINT Biopharma Global Inc., to make progress with respect to PNT2002 across clinical and regulatory manufacturing and commercial readiness work streams, including establishing an expanded access program. In December 2023, Lantheus and POINT Biopharma announced favorable top-line results from the pivotal Phase 3 SPLASH study evaluating the efficacy and safety of PNT2002 in patients with metastatic castration-resistant prostate cancer after progression on an androgen receptor pathway inhibitor.
The Estimate Picture
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. This is not the case here, as you can see below.
Earnings ESP: Lantheus has an Earnings ESP of -1.35%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Stocks Worth a Look
Here are a few other medical stocks worth considering, as these also have the right combination of elements to beat on earnings this reporting cycle.
Esperion Therapeutics, Inc. (ESPR) has an Earnings ESP of +24.53% and a Zacks Rank of 2. ESPR has an estimated long-term growth rate of 46.8%.
Moleculin Biotech, Inc. (MBRX) has an Earnings ESP of +5.00% and is a Zacks #2 Rank stock. MBRX has an estimated growth rate of 20.7% for 2024.
Ardelyx, Inc. (ARDX) has an Earnings ESP of +9.80% and a Zacks Rank of 2. ARDX has a growth rate of 18.5% for 2024.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Zacks Names #1 Semiconductor Stock
It’s only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it’s positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
Esperion Therapeutics, Inc. (ESPR) : Free Stock Analysis Report
Ardelyx, Inc. (ARDX) : Free Stock Analysis Report
Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
